跳至主要内容
临床试验/RBR-8vyvnmb
RBR-8vyvnmb尚未招募2 期

se of Liraglutide to treat Covid19 pneumonia: A Phase II open-label, single center safety study with biomarker profiling

niversidade Federal de São Paulo - Disciplina de Pneumologia0 个研究点开始时间: 2020年12月9日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Intervention

入排标准

年龄范围
18Y 至 0(—)

入选标准

  • Aged over 18 years old; Covid19 pneumonia admitted to hospital less than forty-eight hours including those within a critical care setting

排除标准

  • Anticipated eligibility for extracorporeal membrane oxigenation support in subsequent 72h; life expectancy less than 48h estimated by one or members of the clinical team; impaired liver function, defined as alanine aminotransferase more than 3 times the upper limit of normal; impaired renal function, defined as an estimated glomerular filtration rate less than 30 mL/min/1.73m2; active pancreatitis; known allergy to liraglutide; pregnancy or lactation

研究者

发起方
niversidade Federal de São Paulo - Disciplina de Pneumologia

相似试验